Objective: To determine the minimum incidence and minimum prevalence rates of small-fiber neuropathy (SFN) in a well-defined region in the southern part of the Netherlands.
with (suspected) SFN. The MUMC has a unique position because it is the only hospital in Maastricht and surroundings (most southern part of the Netherlands) providing regional secondary care for patients and thus having an ideal geographical position for epidemiologic research. This region, the basic catchment area of the MUMC, is defined by post-code (zip-code) regions.
We collected data of all patients seen between January 2006 and December 2011 at our institute with (suspected) SFN. Subsequently, all patients living in the basic catchment area of our hospital were selected. For these patients, a validated symptoms inventory questionnaire 12, 14 and results of all additional tests were checked and only those with a definite diagnosis of pure SFN were eventually included in this study. SFN was diagnosed based on the presence of at least 2 of the following symptoms not otherwise explained: neuropathic pain (burning, shooting, prickling, or itching), sheet or sock intolerance, restless legs syndrome, autonomic dysfunction (sicca syndrome, accommodation problems, hyperhidrosis or hypohidrosis, micturition disturbances, impotence and/or diminished ejaculation or lubrication, bowel disturbances, hot flushes, orthostatic dizziness, cardiac palpitations) and clinical signs of small-fiber damage (e.g., pinprick loss, thermal sensory loss, allodynia, or hyperalgesia), normal nerve conduction study, and reduced IENFD at the ankle and/or abnormal quantitative sensory testing thermal thresholds at the foot. 1, 2, 13 Worldwide normative values for age and sex for IENFD measurement with PGP9.5 staining are available for the distal leg. 13 A reduction in IENFD below the fifth percentile is considered confirmatory for a diagnosis of SFN. 5, 13 For Temperature Threshold Testing, we used published normative values according to Yarnitsky. 15 We assessed thresholds at the foot dorsum and the thenar eminence on both sides, using the method of levels and the method of limits. Heat pain was recorded with the method of limits and patients had to immediately react to pain sensation. 4 Abnormality of a measurement was based on z-value statistics, and was considered abnormal when its z value exceeded 2.5. 4 We obtained population numbers for the basic catchment area of the MUMC by sex and age (in the age categories of 0-20, 20-65, and 65 years or older) from Statistics Netherlands, an organization responsible for official Dutch statistics and producing European (community) statistics. 16 On January 1, 2011, there were 205,424 inhabitants in our catchment area, of which 166,203 were 20 years or older (80,350 male). These adults were considered the reference population at risk for the current study. Of these, 126,091 were 20-65 years (62,488 male), whereas 40,112 were 65 years or older (17,862 male).
Using these population numbers from January 1, 2011, we calculated minimum incidence rates for the patients from our basic catchment area with newly diagnosed SFN in 2010 or 2011, and for minimum prevalence rates, we used the data of all patients from our basic catchment area diagnosed with SFN between January 2006 and December 2011.
Standard protocol approvals, registrations, and patient consents. The MUMC's Medical Ethics Committee and Board
of Directors approved this study. According to the Code of Conduct for the use of data in Health Research, 17 for this type of retrospective study, informed consent does not need to be obtained if the data are used anonymously and patients are given the opportunity to object against the use of their medical and personal data for research (which is the case in the MUMC).
RESULTS
Between January 2006 and December 2011, a total of 508 patients have been examined at our SFN center for suspected SFN. Of these, 117 originated from the basic catchment area of our hospital. Twenty-nine patients did not meet the criteria for the diagnosis SFN, leaving 88 patients for this study. Among these 88 eligible patients (mean age 56.9 years, SD 11.8, range 34-81), 49 were males (55.7%; mean age 55.7 years, SD 12.4, range 34-81) and 39 females (44.3%; mean age 58.3 years, SD 10.3, range 39-79). Most patients (98%) were Caucasian. In 52%, an underlying cause for SFN was identified (table 1) . Upon neurologic consultation, nearly 8% of these 88 patients reported having symptoms for more than 10 years. Thirty-five percent of patients experienced burning pain, and autonomic symptoms were reported in 47.7% of the cases (table 2) . Most frequently mentioned autonomic symptoms were sicca symptoms (dry eyes and/or dry mouth) (19.3%), hyperhidrosis (18.2%), and defecation disturbances (13.6%).
In 2010 and 2011, 216 patients were examined; 57 of these patients lived in our basic catchment area of which 39 were diagnosed with definite SFN. Among these 39 patients (mean age 57. 5 3 for additional data on incidence and prevalence). DISCUSSION The current study presents estimated minimum incidence and minimum prevalence rates for the diagnosis of SFN. As shown in table 3, minimum incidence and prevalence rates showed a trend toward higher values in men and in patients aged 65 years and older.
The general annual incidence of 11.73 cases/ 100,000 for SFN is significantly higher than the reported incidence rates in inflammatory large-fiber neuropathies, such as Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP). For example, the reported incidence of GBS in Western countries ranges from 0.89 to 1.89 cases (median 1.11)/100,000 person-years. 18 For CIDP, incidence rates between 1 in 100,000 in southeast United Kingdom and 7.7 in 100,000 in northern Norway have been reported. 19 Because the impact of SFN on quality of life can be as devastating as seen in patients with large-fiber neuropathies, its recognition is equally important. SFN has been receiving increasing attention in the last 15 years, since the introduction of IENFD measurements. 20 The number of patients diagnosed with this general painful neuropathy is increasing rapidly because of better recognition of the disease. 2, 7, 21, 22 This in part explains the number of patients with a long-standing history of symptoms before diagnosis. Where prevalence rates are not influenced by this fact, incidence rates are. We therefore defined an incident case as being newly diagnosed at our SFN center in 2010 or 2011.
Our findings represent minimum incidence and minimum prevalence rates because by far not every patient with SFN will have been recognized and referred to our SFN center. However, we believe that we have estimated the best possible reliable rates by restricting this study to the population of the basic catchment area of our center for which we are the only hospital and therefore also provide regional secondary care. In addition, this population is known to be stable because few people move in and out of this area and because of the nonlethal nature of SFN.
There are some methodologic issues that should be addressed. First, in our study population, sarcoidosis seems to be a common cause of SFN. The recognition of the relation between sarcoidosis and SFN 12,23 has led to an increased awareness, particularly at our center, serving as a tertiary referral center for both sarcoidosis and SFN. Therefore, a selection bias of sarcoidosis as an underlying cause of SFN is conceivable. In our diagnostic workup for SFN, tests for sarcoidosis are included. However, most patients with sarcoidosis were already diagnosed with this disease before being evaluated for suspected SFN. As all other patients, they also underwent testing for other underlying causes of SFN. Sarcoidosis was considered the most likely cause of SFN if no other causes were found. The prevalence of sarcoidosis is known to be higher among African Americans and northern European Caucasians (especially Scandinavians). Because approximately 98% of our SFN patients and 99% of the sarcoidosis patients were western European Caucasian, we believe this did not contribute to the bias toward sarcoidosis. However, interpretation of these points should be done with great caution because the primary aim of the current study was not directed toward the etiology of SFN. Second, the "idiopathic" group is considered a potential Table 2 Reported autonomic symptoms in this cohort of 88 patients with small-fiber neuropathy limitation because (yet undetermined) hereditary causes should be strongly considered. We did not routinely test for all known hereditary sensory and autonomic neuropathies (because of cost limitations). However, many of these neuropathies have specific clinical features generally not compatible with the pure SFN clinical spectrum. 24, 25 In addition, the "idiopathic" group may also contain patients unrecognized as having autoimmunemediated neuropathies such as Sjögren syndrome or neuropathy associated with sicca complex, as many of our patients mentioned sicca symptoms. We routinely performed serology testing (SS-A, SS-B, antinuclear antibodies) as part of the diagnostic workup in all of our patients. If systemic disease was suspected, patients subsequently underwent Schirmer test and lip biopsy. A negative serology does not rule out these conditions, but makes it less likely, especially when combined with a negative Schirmer test and lip biopsy. Under these criteria, none of our patients were diagnosed with Sjögren syndrome. However, it is still possible that an inflammatory condition (including Sjögren) could be an underlying cause. Also, "dry eyes" might actually be corneal hyperalgesia; sensory neuropathy involving the corneal nociceptive system may lead to neuropathic pain, felt and reported as dry eyes. 26 Despite these limitations, the current study presents minimum incidence and minimum prevalence rates of SFN in a well-defined region in the southern part of the Netherlands. These rates are probably an underestimation and are expected to increase in the coming years, since the awareness of SFN is increasing worldwide.
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